Literature DB >> 7024392

Effects of synthetic salmon calcitonin administration on gastrin, immunoreactive insulin and growth hormone release after protein meal in uremic patients.

M Lunetta, E Infantone, D Spanti, L Mughini.   

Abstract

Recent studies indicate that calcitonin inhibits, in man, the secretion of several hormones such as gastrin, insulin, growth hormone. There are no reports about this effect in uremic patients in which frequently calcitonin, gastrin, growth hormone, and insulin response to glucose administration is increased. A comparative study of the effects of synthetic salmon calcitonin infusion (50 U iv) on gastrin, growth hormone and insulin release protein meal (250 g of boiled lean beef) in 10 uremic patients undergoing hemodialysis and in 10 normal subjects was performed. Insulin and growth hormone response to protein meal was inhibited by calcitonin both in normal and uremic subjects. Gastrin response instead was inhibited only in normal subjects. These findings indicate that in uremic patients the inhibitory effect of calcitonin on insulin and growth hormone secretion is still present. The lack of evident inhibitory effect on gastrin release could be related to persistent hypergastrinemia because of the increased half life of the hormone which could mask acute changes of secretion.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7024392     DOI: 10.1007/BF03350449

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  25 in total

1.  Calcitonin inhibition of gastrin secretion in man.

Authors:  T Oyama; M Shiraki; H Ito; K Tanaka; H Orimo
Journal:  Endocrinol Jpn       Date:  1973-12

2.  Radioimmunoassay of human growth hormone.

Authors:  G M Molinatti; F Massara; E Strumia; F Pennisi; G A Scassellati; L Vancheri
Journal:  J Nucl Biol Med       Date:  1969 Jan-Jun

3.  Coated charcoal immunoassay of insulin.

Authors:  V Herbert; K S Lau; C W Gottlieb; S J Bleicher
Journal:  J Clin Endocrinol Metab       Date:  1965-10       Impact factor: 5.958

4.  Inhibitory effect of calcitonin on growth hormone and insulin secretion in man.

Authors:  L Cantalamessa; A Catania; E Reschini; M Peracchi
Journal:  Metabolism       Date:  1978-08       Impact factor: 8.694

5.  [Influence of calcitonin on insulin secretion after intravenous administration of glucose].

Authors:  M Passeri; C Carapezzi; S Ceccato; D Cucinotta; E Palummeri
Journal:  G Clin Med       Date:  1974-05

6.  Effects of hypercalcemia, hypercalcemia and calcitonin on glucose stimulated insulin secretion in man.

Authors:  R Ziegler; S Bellwinkel; D Schmidtchen; H Minne
Journal:  Horm Metab Res       Date:  1972-01       Impact factor: 2.936

7.  Gastrin levels in anephric patients.

Authors:  J G Maxwell; J G Moore; J Dixon; L E Stevens
Journal:  Surg Forum       Date:  1971

8.  Growth hormone in uremia. I. Plasma growth hormone, insulin and glucagon after oral and intravenous glucose in uremic subjects.

Authors:  H Orskov; N J Christensen
Journal:  Scand J Clin Lab Invest       Date:  1971-02       Impact factor: 1.713

9.  Stimulation of gastrin secretion in the pig by parathyroid hormone and its inhibition by thyrocalcitonin.

Authors:  R M Bolman; C W Cooper; S C Garner; P L Munson; S A Wells
Journal:  Endocrinology       Date:  1977-04       Impact factor: 4.736

10.  Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group.

Authors: 
Journal:  Diabetes       Date:  1979-12       Impact factor: 9.461

View more
  2 in total

1.  Synthetic salmon calcitonin is not diabetogenic in patients with normal or impaired glucose metabolism.

Authors:  G Giustina; B Cerudelli; A Cimino; C Rigosa; A Rotondi; E Radaeli
Journal:  J Endocrinol Invest       Date:  1985-02       Impact factor: 4.256

2.  Effect of (8-32) salmon calcitonin, an amylin antagonist, on insulin, glucagon and somatostatin release: study in the perfused pancreas of the rat.

Authors:  R A Silvestre; M Salas; J Rodríguez-Gallardo; O García-Hermida; T Fontela; J Marco
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.